Clinical trials: Tuberculous Meningitis, open to volunteers
Tuberculous Meningitis
Intensified Short Course Regimen for TBM in Adults
Tuberculous meningitis (TBM) is the most lethal form of extra pulmonary tuberculosis. This devastating disease kills almost a third of its sufferers and disables a significant proportion of the survivors.
- Trial name
- INSHORT (NCT05917340)
- Testing
- High dose rifampicin (25mg/kg), Moxifloxacin 400mg, Aspirin 150 mg
- Where
- India
- Volunteers
- 372 people
- Sponsor
- Indian Council of Medical Research
Tuberculosis, Meningitis
Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis
Contezolid is a novel oxazolidinone antibiotic developed by Shanghai Mengke Pharmaceutical Co., Ltd., which successfully went public in 2021.
- Trial name
- NCT06811025
- Testing
- Contezolid, Linezolid (LZD)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Beijing Chest Hospital
Tuberculous Meningitis
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
The purpose of this study is to compare a 6-month regimen of high-dose rifampicin (RIF), high-dose isoniazid (INH), linezolid (LZD), and pyrazinamide (PZA) versus the World Health Organization (WHO) standard of care (SOC)…
- Trial name
- NCT05383742
- Testing
- Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD)
- Where
- 18 sites in Brazil, India and 10 more
- Volunteers
- 330 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculous Meningitis
Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial assessing the efficacity of two interventions to reduce mortality from tuberculous meningitis (TBM) in adolescents and adults…
- Trial name
- INTENSE-TBM (NCT04145258)
- Testing
- Aspirin, WHO TBM treatment, Intensified TBM treatment
- Where
- 13 sites in Côte d’Ivoire, Madagascar and 2 more
- Volunteers
- 768 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculous Meningitis, HIV
BPaLMZ for TB Meningitis
This two-stage study will compare consented research participants with tuberculous meningitis receiving experimental Bedaquiline (B), Pretomanid (Pa), Linezolid (L); Moxifloxacin (M), Pyrazinamide (Z) known as (BPaLMZ) to…
- Conditions
- Tuberculous Meningitis, HIV, Meningitis, TB - Tuberculosis
- Trial name
- BPaLMZ (NCT07227779)
- Testing
- BPaLMZ Regimen
- Where
- 2 sites in Uganda
- Volunteers
- 312 people
- Sponsor
- David Boulware
Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology)
Adjunctive Doxycycline for Central Nervous System Tuberculosis
Although tuberculosis is now considered a treatable disease, central nervous system tuberculosis (CNS-TB) when managed with the current standard-of-care (SOC), still has mortality rates ranging from 30-50% even in tertiary…
- Conditions
- Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System, Tuberculosis; Meningoencephalitis (Etiology)
- Trial name
- DIRECT (NCT06446245)
- Testing
- Doxycycline, Anti Tuberculosis Drug, Adjunctive corticosteroid
- Where
- 6 sites in Indonesia, Malaysia and 1 more
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
Tuberculous Meningitis, HIV I Infection
Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and corticosteroids) in HIV patients with tuberculosis…
- Trial name
- TIMPANI (NCT05590455)
- Testing
- Adalimumab Injection
- Where
- 3 sites in Brazil, Mozambique and 1 more
- Volunteers
- 130 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculosis Meningitis
Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis
AlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity.
- Trial name
- NCT07350174
- Testing
- HRZE, HRZE plus Alpe375, HRZE plus AlpE500
- Volunteers
- 64 people
- Sponsor
- BioVersys AG